KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Exact Sciences (EXAS) Common Equity (2016 - 2025)

Exact Sciences (EXAS) has disclosed Common Equity for 16 consecutive years, with $2.4 billion as the latest value for Q4 2025.

  • On a quarterly basis, Common Equity changed 0.05% to $2.4 billion in Q4 2025 year-over-year; TTM through Dec 2025 was $2.4 billion, a 0.05% change, with the full-year FY2025 number at $2.4 billion, changed 0.05% from a year prior.
  • Common Equity was $2.4 billion for Q4 2025 at Exact Sciences, down from $2.5 billion in the prior quarter.
  • In the past five years, Common Equity ranged from a high of $3.6 billion in Q1 2021 to a low of $2.4 billion in Q1 2025.
  • A 5-year average of $3.0 billion and a median of $3.1 billion in 2023 define the central range for Common Equity.
  • Peak YoY movement for Common Equity: soared 99.78% in 2021, then dropped 23.62% in 2024.
  • Exact Sciences' Common Equity stood at $3.4 billion in 2021, then fell by 10.17% to $3.0 billion in 2022, then grew by 3.36% to $3.1 billion in 2023, then decreased by 23.62% to $2.4 billion in 2024, then decreased by 0.05% to $2.4 billion in 2025.
  • Per Business Quant, the three most recent readings for EXAS's Common Equity are $2.4 billion (Q4 2025), $2.5 billion (Q3 2025), and $2.5 billion (Q2 2025).